Literature DB >> 5539694

[Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].

G Gauthier, J de Ajuriaguerra, F Geissbuhler, B Simona, J Constantinidis, G Yanniotis, M Krassoievitch, J J Eisenring, R Tissot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5539694

Source DB:  PubMed          Journal:  Presse Med        ISSN： 0032-7867            Impact factor:   1.228


× No keyword cloud information.
  5 in total

1.  Gout induced by L-dopa and decarboxylase inhibitors.

Authors:  D B Calne; J Fermaglich
Journal:  Postgrad Med J       Date:  1976-04       Impact factor: 2.401

2.  Demethylation of L-3-methoxytyrosine in vivo.

Authors:  G Bartholini; A Pletscher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

3.  Influence of L-3-methoxytyrosine on monoamine synthesis in rat brain.

Authors:  W Kehr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

4.  Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.

Authors:  F S Messiha; T H Hsu; J R Bianchine
Journal:  J Clin Invest       Date:  1972-02       Impact factor: 14.808

5.  Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.

Authors:  L Rivera-Calimlim
Journal:  Br J Pharmacol       Date:  1974-02       Impact factor: 8.739
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.